The acquisition of ACAM2000 is a strategic fit for Emergent BioSolutions which will enable the latter to expand existing smallpox countermeasure offering along with diversify its portfolio and enabling it to contribute to revenues meaningfully in 2018. Further, it will aid in achieving the goal of $1 billion in total revenues by 2020. The company also expects to generate more than 10% of total revenues from international markets from the deal.